CCR has found a new antibody that can effectively treat small cell lung cancer

Algae glycosin GM1 neuroglycoside lipids (FucGM1) are tumor-related antigens expressed in a large proportion of small cell lung cancer (SCLC) tumors, but most normal adult tissues lack this substance, so it is a potential target for immuno-oncology. Recently, researchers from BMS and Stanford University and other institutions have developed a new type of non-rock algae glycation of the humanized IgG1 antibody BMS-986012, can be specific to target binding FucGM1, researchers in preclinical trials to assess its anti-cancer efficacy, the results of the study published recently in Clin Cancer Res, entitled "A Novel, Full Human Anti-fucosyl-GM1 Antibody Demonstrator Potent In Vitro and In Vivo Antitumor Activity in Preclinical Models of Small Cell Lung Cancer."
researchers evaluated the anti-cancer efficacy of the compound with (or without) chemotherapy drugs and immuno-checkpoint inhibitors using SCLC cell line, mouse allogeneic transplant model, and the same transplant tumor model. The researchers found that BMS-986012 showed a high affinity for Fc-RIIA (CD16), enhancing the antibody's cytotoxicity (ADCC) dependence on antibodies that express FucGM1's cancer cell line. The researchers also observed the tumor-killing effects mediated by BMS-986012 in the Cytotoxicity Experiment (CDC) and the Antibody-Dependent Cell Devouring Experiment (ADCP).
In several mouse SCLC models, the tumor subsides when the dose of the antibody is greater than or equal to 0.3 mg/kg, and the anti-cancer effect is better when used in combination with the standard chemotherapy drug cisplatin or etoposide. In the same-origin transplant model, the researchers treated BMS-986012 or anti-FucGM1 mouse source IgG2a Fc antibodies on tumor models derived from genetically engineered SCLC cells and evaluated their response. When used in union with anti-PD-1 or anti-CD137 antibodies, the therapeutic effect is significantly improved.
, the study found that BMS-986012 alone has a strong anti-cancer effect. It is more effective when used in combination with chemotherapy drugs or immunomodulation drugs. These preclinical data suggest that phase 1 clinical trials of the antibody can be evaluated in SCLC patients with relapse. (Bio Valley)